Bayer to review Roundup's future in U.S. after court setback
By Carl Surran SA News Editor May 26, 2021 10:49 PM ET
Bayer (OTCPK:BAYRY) says it will evaluate whether to continue using glyphosate in its Roundup weedkiller in the residential U.S. market after a judge today rejected its plan to settle future claims alleging the herbicide causes cancer.
Bayer also says it will abandon attempts at a court-approved solution to address its future Roundup liability, and instead will pursue options such as creating a new website with studies relevant to Roundup's safety that could also be reflected on its label.
The company says it will rethink selling glyphosate-based products to U.S. residential consumers - the source of the bulk of lawsuits - while continuing to sell to professional and agricultural users.
The U.S. Environmental Protection Agency has said Roundup is safe and would not permit a cancer warning label, but that leaves the company in a quandary over how to contain liability on a product it sells without any warning label.
Earlier this month, Bayer lost an appeal in one of the three Roundup cases to go to trial.
Now read: Bayer plunges on 'prolonged uncertainty' from Roundup settlement rejection
Note: There are active links contained within the original article linked below.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.